Developer docs
API playgroundTry for free, no card

Search company profiles

Johnson & Johnson China

Full company profile

uuid004p1w5

Namestring
Johnson & Johnson China
Legal namestring
强生(中国)投资有限公司 (Johnson & Johnson (China) Investment Co., Ltd.)
Websiteurl
jnj.com.cn
Company typeenum
Public
Founded yearint
1985
Descriptiontext

Johnson & Johnson China (强生中国) is a wholly-owned operating subsidiary of Johnson & Johnson (NYSE: JNJ), the global healthcare conglomerate founded in 1886 in the United States. The China presence dates to 1985 with the establishment of Xian Janssen Pharmaceutical (西安杨森制药). The company operates three core business segments under the legal holding 强生(中国)投资有限公司 in Shanghai: Innovative Pharmaceuticals (Xian Janssen covering hematology, immunology, oncology, infectious diseases, psychiatry, neurology, dermatology); Medical Technology (强生医疗科技 covering minimally invasive and open surgery, electrophysiology, orthopedics, plastic surgery, and infection prevention); and Vision Care (强生视力健 covering Acuvue contact lenses and ocular health). It operates via three core operating subsidiaries: Xian Janssen (pharma), J&J Medical Devices (Shanghai), and J&J Vision Care Trading (Shanghai), with a manufacturing facility in Xi'an and offices in Shanghai.

Its portfolio includes branded, regulatory-protected products such as HARMONIC® 7s ultrasonic scalpels (manufactured in China since 2025), SURGICEL® absorbable hemostatic particles (approved via China's National Medical Device Innovation Green Channel), ETHICON4000 3D-stapling endoscopic staplers (Asia debut in China 2025), and the Allura (傲诺拉) high-end breast implant line, alongside vision products from the J&J Vision Care business. Go-to-market combines enterprise field sales to hospitals and healthcare institutions for medical technology and pharmaceutical products, plus consumer/retail channels for personal health products. The company also maintains an extensive medical professional education network of 26 institutes that train more than 125,000 healthcare professionals annually, creating professional ecosystem engagement.

Revenue mechanics consist of hardware/device unit sales for medical technology, prescription pharmaceutical sales for Xian Janssen, and consumer product sales for vision care and personal health. China-specific revenue is not separately disclosed by the parent. Recent strategic emphasis is on local manufacturing (China-made HARMONIC 7s), AI-augmented solutions (AFib early detection partnership with Apple on wearables; AI-enabled vision diagnostics partnership with 星创视界/宝岛眼镜), deepening neurointervention localization via the 2026 strategic cooperation with 畅医达, and expanding the innovation ecosystem into the Boao Lecheng International Medical Tourism Pilot Zone.

Short descriptiontext

Johnson & Johnson China is the China subsidiary of NYSE-listed Johnson & Johnson, operating innovative pharmaceuticals (Xian Janssen), medical technology devices, and vision care products. It serves hospitals, healthcare professionals, and Chinese consumers through three wholly-owned operating subsidiaries under a Shanghai holding entity.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
Headquarters上海
HQ citystring
上海
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
innovative pharmaceuticals, medical devices, minimally invasive surgery, vision care products, consumer health products
Industry6 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Pharmaceutical Preparation Manufacturing325412
  • Medical Equipment and Supplies Manufacturing3391
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals and Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1创新制药
TypeOne Time License
Description

强生一直致力于引进和生产高质量的创新产品来满足不断增长的医药卫生需求,产品覆盖血液、免疫、实体肿瘤、传染病、精神科、神经科等领域

jnj.com.cn
2医疗器材
TypeHardware Sales
Description

强生医疗中国主要产品为用于微创及开放性手术、电生理学、骨科、整形等领域的医疗器材

jnj.com.cn
3消费品和个人健康
TypeHardware Sales
Description

强生在消费品和个人健康领域的投资与创新

jnj.com.cn
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1傲诺拉 (ALLURA)
Description

High-end breast implant brand celebrating 10th anniversary in China

jnj.com.cn
+5 more records
Core offering1 text field

Johnson & Johnson China operates a diversified healthcare business in China through three core segments: Innovative Pharmaceuticals (via Xian Janssen), Medical Technology/Medical Devices, and Consumer Health/Personal Care. It develops, manufactures, and commercializes prescription pharmaceuticals across hematology, immunology, oncology, infectious diseases, psychiatry, and neurology; medical devices including surgical staplers, ultrasonic scalpels, hemostatic agents, electrophysiology and orthopedic products; and consumer health products such as contact lenses and breast implants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 强生连续第四次在药品可及性指数排行榜中名列前茅
+2 more records
Product overview1 text field

Johnson & Johnson China operates as a diversified healthcare company with two core business segments: Innovative Pharmaceuticals (创新制药) and Medical Technology (医疗科技). The pharmaceutical business covers hematology, immunology, oncology, infectious diseases, psychiatry, neurology, and dermatology. The medical technology segment provides innovative products for minimally invasive and open surgeries (including wound closure, staplers, ultrasonic scalpels, and absorbable hemostatic gauze), electrophysiology, orthopedics, plastic surgery, and infection prevention. Key branded products include HARMONIC® 7s ultrasonic scalpel (Made in China), SURGICEL® hemostatic materials, 傲诺拉 breast implants, and ETHICON4000 staplers. The company also operates subsidiaries including Xian Janssen Pharmaceutical, J&J Medical Devices China, and Johnson & Johnson Vision Care China.

Product and service7 records
1SURGICEL® (速即纱) Absorbable Hemostatic Particles
CategoryMedical Device - Hemostat
Description

Revolutionary innovative hemostatic product approved via China's National Medical Device Innovation Green Channel; designed to control bleeding during surgical procedures for healthcare professionals and patients.

2HARMONIC® 7s Ultrasonic Scalpel
CategoryMedical Device - Surgical Instrument
Description

China-made (中国智造) ultrasonic scalpel produced by Johnson & Johnson MedTech China for use in surgical procedures, serving Chinese patients with localized innovation.

3傲诺拉星钻 (ALLURA Star Diamond) Breast Implants
CategoryMedical Device - Plastic Surgery
Description

High-end breast implant product under Johnson & Johnson MedTech's ALLURA brand, launched in China celebrating the brand's 10th anniversary; positions technology-empowered natural aesthetics.

4ETHICON4000 Endoscopic Stapler
CategoryMedical Device - Surgical Stapler
Description

Johnson & Johnson global first 3D stereoscopic stapling technology endoscopic stapler, Asia debut landing in China; opens a new era of minimally invasive innovation.

5Catalys Femtosecond Laser Eye Treatment System
CategoryMedical Device - Ophthalmic Surgical System
Description

Johnson & Johnson Vision's femtosecond laser eye treatment system used for cataract surgery, advancing global medical innovation accessibility through charity programs in Boao.

63D Visualization and Magnetic Navigation Dual-Location Electrophysiology Cardiac Surgery Technology
CategoryMedical Device - Cardiac Electrophysiology
Description

Johnson & Johnson MedTech's full-procedure 3D visualization and magnetic-electrical dual-location electrophysiology cardiac surgery technology applied for the first time in a Chinese hospital.

7Innovative Pharmaceuticals Portfolio
CategoryPharmaceuticals
Description

Pharmaceutical products covering hematology (e.g., multiple myeloma), immunology (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis), solid tumors (e.g., prostate cancer), infectious diseases (e.g., HIV, hepatitis, tuberculosis), psychiatry (e.g., schizophrenia), neurology (e.g., depression), colds/cough/fever/digestive, and dermatology/allergies.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1畅医达
Strategic tier核心战略TypeStrategic or Co-development PartnerAnnounced on2026-01-16
Description

强生医疗科技签署战略合作协议,深化神经介入本土创新布局。与畅医达合作再升级,加速创新颅内介入解决方案惠及中国患者

jnj.com.cn
2星创视界(宝岛眼镜)
Strategic tier重要合作TypeStrategic or Co-development PartnerAnnounced on2020-11-09
Description

强生视力健与星创视界(宝岛眼镜)宣布全新战略合作,开启AI赋能智慧诊断创新服务新篇章,呵护视觉健康

jnj.com.cn
Strategic tier重要合作TypeStrategic or Co-development PartnerAnnounced on2019-01-22
Description

强生与苹果合作评估可穿戴设备对AFib早期识别的影响,从而改善诊断和治疗效果。多达30%的AFib病例在直到出现危及生命的并发症时才能得以确诊

4爱可泰隆 (Actelion)
Strategic tier重要收购TypeOthersAnnounced on2017-01-01
Description

2017年强生收购瑞士生物技术公司爱可泰隆(Actelion),为强生带来了世界一流的颠覆性医药产品组合,帮助解决肺动脉高压(PAH)患者的健康需求问题

jnj.com.cn
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Eli Lilly China
TypeDirect peer
Description

Eli Lilly China is a direct peer in branded specialty pharmaceuticals (oncology, immunology, diabetes, neuroscience), pursuing a comparable tier-1 hospital specialty-care strategy and increasingly competing with Xian Janssen for hospital formulary listings.

2AstraZeneca China
TypeDirect peer
Description

AstraZeneca China competes with J&J China across oncology, respiratory, and CV specialty pharma, and has aggressively scaled localized manufacturing and AI-enabled healthcare initiatives in China comparable to J&J's strategy.

TypeDirect peer
Description

Abbott's China entity competes directly with J&J Medical Technology in medtech categories (cardiovascular, electrophysiology, diagnostics, vision) and runs a comparable mix of enterprise hospital sales plus consumer channels.

TypeDirect peer
Description

Medtronic China competes directly with J&J MedTech in surgical devices, electrophysiology, and orthopedic categories, and shares a similar enterprise hospital sales model and exposure to VBP-driven price compression.

TypeDirect peer
Description

Bayer China competes with J&J China across specialty pharma (cardiology, oncology, women's health) and consumer health (OTC, diagnostics), with comparable hospital-channel sales infrastructure and NRDL exposure.

TypeDirect peer
Description

Roche China is a direct peer in specialty oncology, immunology and diagnostics-driven pharma/medtech, mirroring J&J China's diversified pharma + medtech footprint with comparable tier-1 hospital sales coverage.

TypeDirect peer
Description

Sanofi China is a direct peer in specialty pharma (immunology, rare disease, vaccines) and consumer health, with similar NRDL exposure and a comparable mix of branded prescription and OTC portfolios sold through Chinese hospitals and pharmacies.

8Merck Sharp & Dohme (MSD) China
TypeDirect peer
Description

MSD China is a direct peer in oncology, vaccines and specialty pharmaceuticals, with overlapping hospital-channel GTM and similar exposure to NRDL pricing negotiations in China.

TypeDirect peer
Description

Novartis China competes directly with J&J's Xian Janssen in branded specialty pharmaceuticals (cardiology, oncology, immunology, neurology) and operates a similar hospital-enterprise sales motion in tier-1 and tier-2 Chinese cities.

TypeDirect peer
Description

Pfizer's China entity competes head-to-head with J&J China in branded specialty pharmaceuticals (oncology, vaccines, CNS, immunology) and operates a similar hospital-channel commercial model with localized manufacturing and clinical-education infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Johnson & Johnson China

Pharmaceuticals and Medical Devicesjnj.com.cn

Johnson & Johnson China is the China subsidiary of NYSE-listed Johnson & Johnson, operating innovative pharmaceuticals (Xian Janssen), medical technology devices, and vision care products. It serves hospitals, healthcare professionals, and Chinese consumers through three wholly-owned operating subsidiaries under a Shanghai holding entity.

What Johnson & Johnson China does

Johnson & Johnson China (强生中国) is a wholly-owned operating subsidiary of Johnson & Johnson (NYSE: JNJ), the global healthcare conglomerate founded in 1886 in the United States. The China presence dates to 1985 with the establishment of Xian Janssen Pharmaceutical (西安杨森制药). The company operates three core business segments under the legal holding 强生(中国)投资有限公司 in Shanghai: Innovative Pharmaceuticals (Xian Janssen covering hematology, immunology, oncology, infectious diseases, psychiatry, neurology, dermatology); Medical Technology (强生医疗科技 covering minimally invasive and open surgery, electrophysiology, orthopedics, plastic surgery, and infection prevention); and Vision Care (强生视力健 covering Acuvue contact lenses and ocular health). It operates via three core operating subsidiaries: Xian Janssen (pharma), J&J Medical Devices (Shanghai), and J&J Vision Care Trading (Shanghai), with a manufacturing facility in Xi'an and offices in Shanghai.

Its portfolio includes branded, regulatory-protected products such as HARMONIC® 7s ultrasonic scalpels (manufactured in China since 2025), SURGICEL® absorbable hemostatic particles (approved via China's National Medical Device Innovation Green Channel), ETHICON4000 3D-stapling endoscopic staplers (Asia debut in China 2025), and the Allura (傲诺拉) high-end breast implant line, alongside vision products from the J&J Vision Care business. Go-to-market combines enterprise field sales to hospitals and healthcare institutions for medical technology and pharmaceutical products, plus consumer/retail channels for personal health products. The company also maintains an extensive medical professional education network of 26 institutes that train more than 125,000 healthcare professionals annually, creating professional ecosystem engagement.

Revenue mechanics consist of hardware/device unit sales for medical technology, prescription pharmaceutical sales for Xian Janssen, and consumer product sales for vision care and personal health. China-specific revenue is not separately disclosed by the parent. Recent strategic emphasis is on local manufacturing (China-made HARMONIC 7s), AI-augmented solutions (AFib early detection partnership with Apple on wearables; AI-enabled vision diagnostics partnership with 星创视界/宝岛眼镜), deepening neurointervention localization via the 2026 strategic cooperation with 畅医达, and expanding the innovation ecosystem into the Boao Lecheng International Medical Tourism Pilot Zone.

Johnson & Johnson China firmographics

Firmographics
Name
Johnson & Johnson China
Legal name
强生(中国)投资有限公司 (Johnson & Johnson (China) Investment Co., Ltd.)
Website
https://jnj.com.cn
Company type
Public
Founded year
1985
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Johnson & Johnson China is the China subsidiary of NYSE-listed Johnson & Johnson, operating innovative pharmaceuticals (Xian Janssen), medical technology devices, and vision care products. It serves hospitals, healthcare professionals, and Chinese consumers through three wholly-owned operating subsidiaries under a Shanghai holding entity.
Ownership category
akta.pro rank

Johnson & Johnson China industry classification

Industry
Product category
Pharmaceuticals and Medical Devices
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Innovative pharmaceuticals
  • Medical devices
  • Minimally invasive surgery
  • Vision care products
  • Consumer health products

Where Johnson & Johnson China is headquartered

Location

Headquarters

HQ city
上海

Offices4 records

Markets served

Johnson & Johnson China business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. 创新制药: 强生一直致力于引进和生产高质量的创新产品来满足不断增长的医药卫生需求,产品覆盖血液、免疫、实体肿瘤、传染病、精神科、神经科等领域
  2. 医疗器材: 强生医疗中国主要产品为用于微创及开放性手术、电生理学、骨科、整形等领域的医疗器材
  3. 消费品和个人健康: 强生在消费品和个人健康领域的投资与创新

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Johnson & Johnson China product offering

Product offering

Core offering

Johnson & Johnson China operates a diversified healthcare business in China through three core segments: Innovative Pharmaceuticals (via Xian Janssen), Medical Technology/Medical Devices, and Consumer Health/Personal Care. It develops, manufactures, and commercializes prescription pharmaceuticals across hematology, immunology, oncology, infectious diseases, psychiatry, and neurology; medical devices including surgical staplers, ultrasonic scalpels, hemostatic agents, electrophysiology and orthopedic products; and consumer health products such as contact lenses and breast implants.

Product overview

Johnson & Johnson China operates as a diversified healthcare company with two core business segments: Innovative Pharmaceuticals (创新制药) and Medical Technology (医疗科技). The pharmaceutical business covers hematology, immunology, oncology, infectious diseases, psychiatry, neurology, and dermatology. The medical technology segment provides innovative products for minimally invasive and open surgeries (including wound closure, staplers, ultrasonic scalpels, and absorbable hemostatic gauze), electrophysiology, orthopedics, plastic surgery, and infection prevention. Key branded products include HARMONIC® 7s ultrasonic scalpel (Made in China), SURGICEL® hemostatic materials, 傲诺拉 breast implants, and ETHICON4000 staplers. The company also operates subsidiaries including Xian Janssen Pharmaceutical, J&J Medical Devices China, and Johnson & Johnson Vision Care China.

Differentiator

Problem solved

Functional benefit

Brands

  • 傲诺拉 (ALLURA): High-end breast implant brand celebrating 10th anniversary in China
  • 西安杨森 (Xian Janssen)
  • SURGICEL (速即纱)
  • HARMONIC (超声刀)
  • ETHICON
  • 强生全视 (Johnson & Johnson Vision)

Products and services

  • SURGICEL® (速即纱) Absorbable Hemostatic Particles Revolutionary innovative hemostatic product approved via China's National Medical Device Innovation Green Channel; designed to control bleeding during surgical procedures for healthcare professionals and patients.
  • HARMONIC® 7s Ultrasonic Scalpel China-made (中国智造) ultrasonic scalpel produced by Johnson & Johnson MedTech China for use in surgical procedures, serving Chinese patients with localized innovation.
  • 傲诺拉星钻 (ALLURA Star Diamond) Breast Implants High-end breast implant product under Johnson & Johnson MedTech's ALLURA brand, launched in China celebrating the brand's 10th anniversary; positions technology-empowered natural aesthetics.
  • ETHICON4000 Endoscopic Stapler Johnson & Johnson global first 3D stereoscopic stapling technology endoscopic stapler, Asia debut landing in China; opens a new era of minimally invasive innovation.
  • Catalys Femtosecond Laser Eye Treatment System Johnson & Johnson Vision's femtosecond laser eye treatment system used for cataract surgery, advancing global medical innovation accessibility through charity programs in Boao.
  • 3D Visualization and Magnetic Navigation Dual-Location Electrophysiology Cardiac Surgery Technology Johnson & Johnson MedTech's full-procedure 3D visualization and magnetic-electrical dual-location electrophysiology cardiac surgery technology applied for the first time in a Chinese hospital.
  • Innovative Pharmaceuticals Portfolio Pharmaceutical products covering hematology (e.g., multiple myeloma), immunology (e.g., rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis), solid tumors (e.g., prostate cancer), infectious diseases (e.g., HIV, hepatitis, tuberculosis), psychiatry (e.g., schizophrenia), neurology (e.g., depression), colds/cough/fever/digestive, and dermatology/allergies.

Quantifiable outcome

  • 强生连续第四次在药品可及性指数排行榜中名列前茅
  • +2 more outcomes

Companies that use Johnson & Johnson China

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Johnson & Johnson China technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature4 records

Johnson & Johnson China partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered 核心战略, 重要合作 and 重要收购.

  • 畅医达核心战略Strategic or Co-development Partner · 16 January 2026强生医疗科技签署战略合作协议,深化神经介入本土创新布局。与畅医达合作再升级,加速创新颅内介入解决方案惠及中国患者
  • 星创视界(宝岛眼镜)重要合作Strategic or Co-development Partner · 9 November 2020强生视力健与星创视界(宝岛眼镜)宣布全新战略合作,开启AI赋能智慧诊断创新服务新篇章,呵护视觉健康
  • 苹果 (Apple)重要合作Strategic or Co-development Partner · 22 January 2019强生与苹果合作评估可穿戴设备对AFib早期识别的影响,从而改善诊断和治疗效果。多达30%的AFib病例在直到出现危及生命的并发症时才能得以确诊
  • 爱可泰隆 (Actelion)重要收购Others · 1 January 20172017年强生收购瑞士生物技术公司爱可泰隆(Actelion),为强生带来了世界一流的颠覆性医药产品组合,帮助解决肺动脉高压(PAH)患者的健康需求问题

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Johnson & Johnson China competitors and assessment

Company assessment

Direct peers

  • Eli Lilly China: Eli Lilly China is a direct peer in branded specialty pharmaceuticals (oncology, immunology, diabetes, neuroscience), pursuing a comparable tier-1 hospital specialty-care strategy and increasingly competing with Xian Janssen for hospital formulary listings.
  • AstraZeneca China: AstraZeneca China competes with J&J China across oncology, respiratory, and CV specialty pharma, and has aggressively scaled localized manufacturing and AI-enabled healthcare initiatives in China comparable to J&J's strategy.
  • Abbott China: Abbott's China entity competes directly with J&J Medical Technology in medtech categories (cardiovascular, electrophysiology, diagnostics, vision) and runs a comparable mix of enterprise hospital sales plus consumer channels.
  • Medtronic China: Medtronic China competes directly with J&J MedTech in surgical devices, electrophysiology, and orthopedic categories, and shares a similar enterprise hospital sales model and exposure to VBP-driven price compression.
  • Bayer China: Bayer China competes with J&J China across specialty pharma (cardiology, oncology, women's health) and consumer health (OTC, diagnostics), with comparable hospital-channel sales infrastructure and NRDL exposure.
  • Roche China (Roche Diagnostics + Roche Pharma): Roche China is a direct peer in specialty oncology, immunology and diagnostics-driven pharma/medtech, mirroring J&J China's diversified pharma + medtech footprint with comparable tier-1 hospital sales coverage.
  • Sanofi China: Sanofi China is a direct peer in specialty pharma (immunology, rare disease, vaccines) and consumer health, with similar NRDL exposure and a comparable mix of branded prescription and OTC portfolios sold through Chinese hospitals and pharmacies.
  • Merck Sharp & Dohme (MSD) China: MSD China is a direct peer in oncology, vaccines and specialty pharmaceuticals, with overlapping hospital-channel GTM and similar exposure to NRDL pricing negotiations in China.
  • Novartis China: Novartis China competes directly with J&J's Xian Janssen in branded specialty pharmaceuticals (cardiology, oncology, immunology, neurology) and operates a similar hospital-enterprise sales motion in tier-1 and tier-2 Chinese cities.
  • Pfizer China: Pfizer's China entity competes head-to-head with J&J China in branded specialty pharmaceuticals (oncology, vaccines, CNS, immunology) and operates a similar hospital-channel commercial model with localized manufacturing and clinical-education infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Johnson & Johnson China social profiles

Digital presence

Johnson & Johnson China compliance and trust

Trust signal

Compliance2 records

Johnson & Johnson China financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Johnson & Johnson China leadership team

Management profile

Number of profiles

Profiles6 records

Johnson & Johnson China subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Johnson & Johnson China funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Johnson & Johnson China M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Johnson & Johnson China

What does Johnson & Johnson China do?

Johnson & Johnson China operates a diversified healthcare business in China through three core segments: Innovative Pharmaceuticals (via Xian Janssen), Medical Technology/Medical Devices, and Consumer Health/Personal Care. It develops, manufactures, and commercializes prescription pharmaceuticals across hematology, immunology, oncology, infectious diseases, psychiatry, and neurology; medical devices including surgical staplers, ultrasonic scalpels, hemostatic agents, electrophysiology and orthopedic products; and consumer health products such as contact lenses and breast implants.

Is Johnson & Johnson China a public or private company?

Johnson & Johnson China is a public company. It is classified as public and is currently operating.

When was Johnson & Johnson China founded?

Johnson & Johnson China was founded in 1985. It employs 1,001 to 5,000 people.

Where is Johnson & Johnson China based?

Johnson & Johnson China is headquartered in 上海.

How does Johnson & Johnson China make money?

Three revenue lines are on record. 创新制药 is the primary driver. The others are 医疗器材 and 消费品和个人健康.

Who are Johnson & Johnson China's main competitors?

Direct peers on record are Eli Lilly China, AstraZeneca China, Abbott China, Medtronic China, Bayer China, Roche China (Roche Diagnostics + Roche Pharma), Sanofi China, Merck Sharp & Dohme (MSD) China, Novartis China and Pfizer China.

Does Johnson & Johnson China have an API?

No public API is recorded for Johnson & Johnson China.

What industry is Johnson & Johnson China in?

Johnson & Johnson China's product category is Pharmaceuticals and Medical Devices. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals